Supporting this possibility is the finding that in a specific setting of Her2-neu, ER and PR expression in the tumors, IL-1β was identified as a risk factor for disease recurrence, suggesting that it can act jointly with other pro-malignancy factors to promote disease progression in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.